Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition between Humira and Imraldi in adults with Crohn's disease
ISRCTN11094929Phase 4Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, single-blind trial of adalimumab in Crohn's disease (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Maintenance of baseline clinical status at week 24 and Maintenance of baseline clinical status at week 48. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN11094929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11094929.